PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2011
CASE
AUTH/2449/11/11 Boehringer Ingelheim ⭐ Case of the Week

Boehringer Ingelheim & Lilly: Trajenta β€œControl and care matter” leavepiece – no breach (AUTH/2449/11/11, AUTH/2450/11/11)

A GP alleged Trajenta β€œwith a difference” claims were misleading vs other DPP-4 inhibitors (dose adjustment, renal monitoring, food). Panel and Appeal…

2013
CASE
AUTH/2579/2/13 Bayer

Bayer: β€˜Mirena training workshop’ weblink found misleading (EvoInserter training expectation) β€” AUTH/2579/2/13

A GP said he was misled into attending what he thought was EvoInserter training for Mirena. PMCPA found the β€˜Mirena training workshop’…

2012
CASE
AUTH/2556/11/12 Janssen

Janssen: Sponsorship of ISU urology meeting in Belfast raised hospitality concerns (AUTH/2556/11/12)

Anonymous NHS HCPs complained about excessive hospitality at a 5-star Belfast urology meeting with golf and a gala dinner. Janssen was found…

2013
CASE
AUTH/2602/5/13 Chugai

AUTH/2602/5/13: Anonymous v Chugai Pharma UK – Provision of hospitality (No breach)

Anonymous complaint alleged Chugai staff bought rounds of drinks for health professionals in a hotel bar after a conference dinner. Chugai denied…

2012
CASE
Abbott Healthcare Products

Abbott breached ABPI Code after Hidrasec ads appeared on Facebook (public promotion of POM)

A GP complained that Hidrasec ads were visible on Facebook. The Panel ruled this effectively promoted a prescription-only medicine to the public…

2013
CASE
AUTH/2633/8/13 Leo Pharma ⭐ Case of the Week

Leo Pharma: Picato β€˜Dear Dr’ template letter pad alleged to bypass non-formulary status (AUTH/2633/8/13) – No breach

A pharmacist alleged Leo’s pre-printed β€˜Dear Dr’ forms for Picato were used to bypass local formulary status. PMCPA found the material didn’t…

2013
CASE
AUTH/2590/3/13 Shire Pharmaceuticals

AUTH/2590/3/13: Shire voluntary admission over Lancet reprint bar chart (Replagal) – no breach

Shire self-referred use of a Lancet reprint containing an incorrect bar chart about competitor Fabrazyme. Although the correction was included at the…

2014
CASE
AUTH/2698/1/14 Astellas Pharma

AUTH/2698/1/14: Astellas – misleading sponsorship declaration in BMJ supplement (Vesomni launch)

Astellas admitted an error in a BMJ-distributed β€œconsensus statement” where the sponsorship declaration understated its role. The Panel found disguised promotion, misleading…

2015
CASE
AUTH/2817/12/15 Bausch

AUTH/2817/12/15: ALK-AbellΓ³/Director v Bausch & Lomb β€” breach of undertaking over β€œnew” claim on Emerade website

Bausch & Lomb was ruled in breach after β€œnew” claims for Emerade remained on an HCP website page despite an undertaking in…

2015
CASE
AUTH/2814/12/15 Boehringer Ingelheim

AUTH/2814/12/15: Boehringer Ingelheim symposia at ESC Congress (Pradaxa) – no breach, but Panel raised concern about unlicensed reversal agent slide

Complaint alleged off-label discussion and research grant promotion at a Boehringer Ingelheim ESC 2015 symposium. Panel found no evidence of off-label promotion…

2015
CASE
AUTH/2785/8/15 Bayer ⭐ Case of the Week

Bayer Eylea promotion: misleading implied comparison with unlicensed Lucentis dose in DMO e-detailer (AUTH/2785/8/15)

PMCPA found Bayer’s DMO e-detailer/briefing implied Eylea superiority vs Lucentis using unlicensed Lucentis dosing without clear status. Breaches of Clauses 7.2, 7.3,…

2015
CASE
AUTH/2751/3/15 ViiV

ViiV Healthcare: Triumeq BMJ ad and comparison vs Atripla in treatment-naΓ―ve patients (AUTH/2751/3/15)

Anonymous GP challenged Triumeq BMJ ad claims (β€œinner strength” and superiority vs Atripla in treatment-naΓ―ve patients). Panel found a narrow breach of…

2014
CASE
AUTH/2735/9/14 Bayer

Bayer HealthCare: HSJ bound-in supplement found to disguise promotional nature and inadequately declare sponsorship (AUTH/2735/9/14)

A Bayer-sponsored HSJ bound-in supplement on DVT care was ruled to disguise its promotional nature and failed to make sponsorship sufficiently prominent…

2014
CASE
AUTH/2722/7/14 Orion Pharma

Orion Pharma UK: respiratory review service seen as a switching mechanism for Easyhaler (AUTH/2722/7/14)

Anonymous ex-employee alleged Orion-funded respiratory reviews were used to drive cost-based switching to Easyhaler. Panel found the combined effect of sales briefings…

2014
CASE
AUTH/2706/3/14 Tillotts Pharma UK

Tillotts detail aid on Octasa vs Asacol dissolution profiles ruled misleading (but no breach of prior undertaking): AUTH/2706/3/14

A Tillotts Octasa detail aid compared dissolution profiles with Asacol. The Panel ruled the page misleading (Clause 7.2) because it implied clinical…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training